The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
BioStock Studio: Scandion Oncology brings in New CEO
Scandion Oncology’s top candidate, SCO-101, is currently in a phase II clinical trial with metastatic colorectal cancer patients. As the study progresses, the company is beginning a new phase in its development program. In light of this, the company has appointed Bo Rode Hansen as CEO, while former CEO Nils Brünner takes the role as CSO, to strengthen its executive leadership. Both Rode Hansen and Brünner came to the BioStock studio to discuss the change.
Notiser
Nosa Plugs expanderar till Norge
BrainCool pausar stroke-studie
PHI får ny vd
AcouSort utökar europeiskt samarbete
Integrum stärker distribution i Ukraina
NYHETSBREV
NYHETER
Lovande preliminära resultat för Elicera Therapeutics CAR T-cellstudie
Active Biotech stiger på lovande data
Cereno Scientific går framåt på bred front under Q1
Kommande event!
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
Krönikor
Fruergaard Jørgensen lämnar – något är på tok
Första draget gjort – nu väntar vi på svar
